Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$3.7 million.

  • Protalix BioTherapeutics' Cash from Operations fell 19091.35% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year decrease of 22118.87%. This contributed to the annual value of $8.7 million for FY2024, which is 75811.84% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Cash from Operations stood at -$3.7 million for Q3 2025, which was down 19091.35% from -$5.2 million recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Cash from Operations high stood at $6.5 million for Q2 2021, and its period low was -$9.8 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$3.6 million (2024), whereas its average is -$2.2 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Cash from Operations crashed by 38957.45% in 2022 and then skyrocketed by 23969.31% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Cash from Operations stood at -$5.1 million in 2021, then skyrocketed by 48.67% to -$2.6 million in 2022, then skyrocketed by 237.69% to $3.6 million in 2023, then increased by 11.02% to $4.0 million in 2024, then tumbled by 193.51% to -$3.7 million in 2025.
  • Its Cash from Operations stands at -$3.7 million for Q3 2025, versus -$5.2 million for Q2 2025 and -$5.1 million for Q1 2025.